Head and neck region consolidation radiotherapy and prophylactic cranial irradiation with hippocampal avoidance delivered with helical tomotherapy after induction chemotherapy for non-sinonasal neuroendocrine carcinoma of the upper airways

Radiation Oncology

Umberto Ricardi⁸  Franca Ozzello⁵  Santi Tofani²  Massimo Pasquino²  Valeria Casanova Borca²  Giuseppe Girelli⁶  Maria Rosa La Porta⁶  Paolo Canzi⁴  Pierpaolo Carassai⁷  Piera Sciacero⁶  Paola Ceroni³  Domenico Cante⁶  Paola Catuzzo³  Fernanda Migliaccio⁵  Gianmauro Numico¹  Pierfrancesco Franco⁵ 

[1] Medical Oncology Department, Ospedale Regionale 'U.Parini', AUSL Valle d'Aosta, Viale Ginevra n° 3, 11100 Aosta, Italy;Medical Physics Department, ASL TO4, Ospedale Civile di Ivrea, Ivrea, Italy;Medical Physics Department, Ospedale Regionale 'U.Parini', AUSL Valle d'Aosta, Viale Ginevra n° 3, 11100 Aosta, Italy;ENT Department, Ospedale Regionale 'U.Parini', AUSL Valle d'Aosta, Viale Ginevra n° 3, 11100 Aosta, Italy;Radiation Oncology Department, Tomotherapy Unit, Ospedale Regionale 'U.Parini', AUSL Valle d'Aosta, Viale Ginevra n° 3, 11100 Aosta, Italy;Radiotherapy Department, ASL TO4, Ospedale Civile di Ivrea, Ivrea, Italy;Pathology Department, Ospedale Regionale 'U.Parini', AUSL Valle d'Aosta, Viale Ginevra n° 3, 11100 Aosta, Italy;Department of Medical and Surgical Sciences, Radiation Oncology Unit, University of Torino, Ospedale San Giovanni Battista, Turin, Italy

关键词: Prophylactic cranial irradiation;    Hippocampus avoidance;    Head and neck;    Non-sinonasal neuroendocrine carcinoma;    Tomotherapy;    Radiotherapy;   

Others  :  1160895
DOI  :  10.1186/1748-717X-7-21

 received in 2011-12-19, accepted in 2012-02-15,  发布年份 2012

【 摘 要 】

Background

Non-sinonasal neuroendocrine carcinomas (NSNECs) of the head and neck are considered an unfrequent clinico-pathological entity. Combined modality treatment represents an established therapeutic option for undifferentiated forms where distant metastasis is a common pattern of failure.

Methods

We report on a case of NSNEC treated with sequential chemo-radiation consisting of 6 cycles of cisplatin and etoposide followed by loco-regional radiation to the head and neck and simultaneous prophylactic cranial irradiation to prevent from intracranial spread, delivered with helical tomotherapy with the 'hippocampal avoidance' technique in order to reduce neuro-cognitive late effects.

Results

One year after the end of the whole combined modality approach, the patient achieved complete remission, with no treatment-related sub-acute and late effects.

Conclusions

The present report highlights the importance of multidisciplinary management for NSNECs of the head and neck, as the possibility to achieve substantial cure rates with mild side effects with modern radiotherapy techniques.

【 授权许可】

   
2012 Franco et al; BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Barker JL, Glisson BS, Garden AS, et al.: Management of nonsinonasal neuroendocrine carcinomas of the head and neck. Cancer 2003, 98:2322-2328.
• [2]Ibrahim NBN, Briggs JC, Corbyshley CM: Extrapulmonary oat cell carcinoma. Cancer 1984, 54:1645-1661.
• [3]Mills SE: Neuroendocrine tumors of the head and neck: a selected review with emphasis on terminology. Endocr Pathol 1996, 7:329-343.
• [4]Likhacheva A, Rosenthal DI, Hanna E, Kupferman M, DeMonte F, El-Naggar AK: Sinonasal neuroendocrine carcinoma: impact of differentiation status on response and outcome. Head and Neck Oncology 2011, 3:32. BioMed Central Full Text
• [5]Capelli M, Bertino G, Morbini P, Villa C, Zorzi S, Benazzo M: Neuroendocrine carcinomas of the upper airways: a small case series with histopatological considerations. Tumori 2007, 93:499-503.
• [6]Brisigotti M, Fabretti G, Lanzanova G, Brugnari ER, Presutti L, Artoni S: Atypical carcinoid of the larynx: case report. Tumori 1987, 73:417-421.
• [7]Procopio G, Ricotta R, Fusi A, et al.: Neuroendocrine tumors of the larynx: a clinical report and literature review. Tumori 2006, 92:72-75.
• [8]Gondi V, Tomé W, Metha MP: Why avoid the hippocampus? A Review. Radiother Oncol 2010, 97:370-376.
• [9]Robbins KT: Integrating radiological criteria into the classification of cervical lymph node disease. Arch Otolaryngol Head Neck Surg 1999, 125:385-387.
• [10]Gondi V, Tolakanahalli R, Mehta MP, et al.: Hippocampal-sparing whole-brain radiotherapy: a 'How-to' technique using helical tomotherapy and linear-accellerator-based intensity-modulated radiotherapy. Int J Radiat Oncol Bio Phys 2010, 78:1244-1252.
• [11]Rancati T, Schwarz M, Allen AM, et al.: Radiation dose-volume effects in the larynx and pharynx. Int J Radiat Oncol Biol Phys 2010, 76:S64-S69.
• [12]Deasey JO, Moiseenko V, Marks L, Chao C, Nam J, Eisbruch A: Radiotherapy dose-volume effects on salivary gland function. Int J Radiat Oncol Biol Phys 2010, 76:S58-S63.
• [13]Bhandare N, Jackson A, Eisbruch A, et al.: Radiation therapy and hearing loss. Int J Radiat Oncol Biol Phys 2010, 76:S50-S57.
• [14]Mayo C, Martel MK, Marks LB, Flickinger J, Nam J, Kirkpatrick J: Radiation dose-volume effects of optic nerves and chiasm. Int J Radiat Oncol Biol Phys 2010, 76:S28-S35.
• [15]Corvo' R: Evidence-based radiation oncology in head and neck squamous cell carcinoma. Radiother Oncol 2007, 85:156-170.
• [16]Boushey RP, Dackwick AP: Carcinoid tumors. Curr Treat Options Oncol 2002, 3:319-326.
• [17]Jassem J: The role of radiotherapy in lung cancer: where is the evidence? Radiother Oncol 2007, 83:203-213.
• [18]Mackie TR, Balog J, Ruchala K, et al.: Tomotherapy. Semin Radiat Oncol 1999, 9:108-117.
• [19]Mackie TR, Holmes T, Swerdloff S, et al.: Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy. Med Phys 1993, 20:1709-1719.
• [20]Meyers CA, Brown PD: Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumours. J Clin Oncol 2006, 24:1305-1309.
• [21]Gondi V, Tome WA, Marsh J, et al.: Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: safety profile for RTOG 0933. Radiother Oncol 2010, 95:327-331.
• [22]Meyers CA, Wefel JS: The use of the mini-mental status examnation to assess cognitive function in cancer trials: no ifs, ands, buts or sensitivity. J Clin Oncol 2003, 21:3557-3558.
• [23]Scoccianti S, Ricardi U: Treatment of brain metastasis: review of phase III randomized trials. Radiother Oncol, in press. http://dx.doi.org/10.1016/j.bbr.2011.03.031 webcite